Andrew Beardsley, MD
Hematology & Oncology · Asheville, NCNPI 1881855948
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.6% of the total across 114 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $999, 6.4 times the $157 reported in 2019.
Across 114 payments — averaging $22.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$368
- Johnson & Johnson$298
- AstraZeneca$273
- Medtronic$157
- Pfizer$156
- Incyte Corporation$142
- plus $1K from 32 others
Across 60 payments — averaging $14,170 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$576K
- AstraZeneca$108K
- Regeneron$74K
- E.r. Squibb & Sons, L.L.C.$66K
- Beigene, Ltd.$26K
What the payments were for
- Food & beverage$2,30891%
- Education$2409%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 14 | $368 |
| Johnson & Johnson | 17 | $298 |
| AstraZeneca(2 entities) | 11 | $273 |
| Medtronic | 1 | $157 |
| Pfizer | 10 | $156 |
| Incyte Corporation | 3 | $142 |
| Merck | 7 | $140 |
| AbbVie | 5 | $94 |
| GSK | 3 | $63 |
| Array Biopharma Inc | 3 | $62 |
| Mirati Therapeutics, Inc. | 2 | $51 |
| Seagen Inc. | 2 | $49 |
| Kyowa Kirin, Inc. | 3 | $45 |
| Beone Medicines USA, Inc. | 2 | $43 |
| Bayer | 2 | $42 |
| Eisai Inc. | 2 | $40 |
| Legend Biotech USA Inc. | 1 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Boehringer Ingelheim | 2 | $37 |
| Dendreon Pharmaceuticals LLC | 1 | $33 |
| Myriad Genetic Laboratories, Inc. | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Ipsen Biopharmaceuticals, Inc | 2 | $28 |
| Astellas Pharma US Inc | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Bristol Myers Squibb | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Genmab U.S., Inc. | 1 | $21 |
| Servier Pharmaceuticals LLC | 1 | $21 |
| Acrotech Biopharma Inc. | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $20 |
| Syndax Pharmaceuticals, Inc. | 1 | $19 |
| AVEO Pharmaceuticals, Inc. | 1 | $18 |
| Stemline Therapeutics Inc. | 1 | $18 |
| Adaptive Biotechnologies Corporation | 1 | $17 |
| Epizyme, Inc. | 1 | $14 |
| Spectrum Pharmaceuticals Inc. | 1 | $13 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,548 in reported general payments places this provider in the 55th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 32 | $673,466 |
| RevlimidLenalidomide | 35 | $551,282 |
| PomalystPomalidomide | 22 | $467,792 |
| ImbruvicaIbrutinib | 38 | $457,712 |
| AlecensaAlectinib Hcl | 23 | $391,464 |
| ImfinziDurvalumab | 41 | $350,224 |
| VenclextaVenetoclax | 32 | $343,128 |
| InlytaAxitinib | 18 | $258,478 |
| Abiraterone Acetate | 84 | $129,577 |
| Lupron DepotLeuprolide Acetate | 18 | $117,388 |
| Imatinib Mesylate | 22 | $67,642 |
| EliquisApixaban | 90 | $63,959 |
| Ondansetron OdtOndansetron | 128 | $2,847 |
| Oxycodone Hcl | 101 | $2,583 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 34 | $1,316 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso, Imfinzi | $273 | $1,023,69173 claims |
| Bristol Myers SquibbRevlimid | $25 | $551,28235 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $28 | $467,79222 claims |
| AbbVieVenclexta, Lupron Depot | $94 | $460,51550 claims |
| PfizerInlyta, Eliquis | $156 | $322,437108 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 358 hematology & oncology providers in North Carolina.
Other hematology & oncology in Asheville
- Sean WarschAsheville$37K
- Amit MehtaCary$4.3M
- Michael MorseDurham$2.6M
- Shelbi AtrashCharlotte$994K
- Phillip FebboDurham$749K
- Angela AlistarWinston Salem$509K
- Ravi PaluriWinston Salem$314K
- Matthew McKinneyDurham$277K
- Jared WeissChapel Hill$217K
- Joshua ZeidnerChapel Hill$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.